Application of Time Restriction Feeding in Patients With Type 2 Diabetes Mellitus

Sponsor
OhioHealth (Other)
Overall Status
Recruiting
CT.gov ID
NCT05015504
Collaborator
Ohio University (Other)
30
1
1
28.6
1

Study Details

Study Description

Brief Summary

In this 3-week interventional study, the investigators hypothesize that therapeutic Time-Restricted Feeding in patients with poorly controlled Type 2 diabetes mellitus (T2DM) can improve their mean glucose or estimated glycated hemoglobin levels with the same dose, or even reduced dose, of antidiabetics.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Time restricted feeding
N/A

Detailed Description

Time-restricted feeding (TRF) has recently gained popularity as a means of reducing body weight and improving glycemia. A recent clinical trial in men who had prediabetes showed that TRF for five weeks significantly reduced fasting insulin concentration and improved the derived oral glucose tolerance test ( OGTT) indexes of beta-cell responsiveness and insulin resistance. However, the effects of TRF have not been studied in patients with poorly controlled Type 2 diabetes mellitus (T2DM). In this 3-week interventional self-controlled clinical trial, the investigators hypothesize that TRF in patients with poorly-controlled T2DM can improve their mean glucose with the same dose/reduced dose of antidiabetics. Potential study subjects will be identified from Endocrinology clinic patients with a diagnosis of poorly controlled type 2 DM (A1c >= 8.0 in the 3 months before enrollment) based on inclusion and exclusion criteria. All study subjects will be in the ad libitum feeding phase for one week, and then will be placed on time-restricted fasting (feeding between 4 AM

  • 4 PM, fasting in the rest of the day) for the second week. For the third and final week, patients will be returned to the ad libitum feeding phase. The first and third weeks will serve as the control phases, and the second week will be the experimental phase. The mean glucose, serum triglyceride levels, insulin resistance, and body weights will be compared between the two phases. Results of this clinical study may demonstrate a low-cost and practical way of diabetic control.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single group self comparisonSingle group self comparison
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Application of Time Restriction Feeding in Patients With Type 2 Diabetes Mellitus
Actual Study Start Date :
Feb 10, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Time restricted feeding

The study will consist of three phases. In phase I all study subjects will be in the ad libitum feeding phase for one week followed by Phase II. In Phase II the subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week. For phase III (final week), patients will be returned to an ad libitum feeding. The first and third phases will serve as control phases, and the second phase will be the experimental phase

Behavioral: Time restricted feeding
In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
Other Names:
  • Ad libitum feeding
  • Outcome Measures

    Primary Outcome Measures

    1. mean glucose [in one week of time restricted feeding]

      change in mean glucose

    2. estimated hemoglobin A1c levels [in one week of time restricted feeding]

      change in estimated hemoglobin A1c levels

    Secondary Outcome Measures

    1. Insulin resistance [in one week of time restricted feeding]

      change in Insulin resistance is represented by the homeostatic model of assessment of insulin resistance

    2. serum triglyceride levels [in one week of time restricted feeding]

      change serum triglycerides are measured by a fasting lipid panel

    3. body weight [in one week of time restricted feeding]

      change in body weight

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age ≥ 18 years and < 65 years

    • With the diagnosis of type 2 diabetes

    • A1c >= 8.0 on the most recent test in the 3 months before enrollment

    • Have been on stable antidiabetics in the 3 months before enrollment

    • OhioHealth Patient

    Exclusion Criteria:
    • Pregnant or breastfeeding patients

    • Severe hypoglycemic episodes (defined as having low blood glucose levels that requires assistance from another person to treat) in the past 12 months

    • Unable to give informed consent

    • Currently enrolled in another therapeutic study

    • Thyroid dysfunction, as defined by abnormal thyroid function test results within the past 6 months

    • Advanced stage of renal (stage 4 or above) or hepatic (cirrhosis) or respiratory (needs oxygen) or heart failure (NYHA class 3 or above)

    • Active infection or malignancy

    • Dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting

    • Clinician-reported history of patient non-adherence

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 OhioHealth Castrop Health Center Athens Ohio United States 45701

    Sponsors and Collaborators

    • OhioHealth
    • Ohio University

    Investigators

    • Principal Investigator: Yuanjie Mao, MD, PhD, OhioHealth

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    OhioHealth
    ClinicalTrials.gov Identifier:
    NCT05015504
    Other Study ID Numbers:
    • 1770741-4
    First Posted:
    Aug 20, 2021
    Last Update Posted:
    Feb 11, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by OhioHealth
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 11, 2022